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A B S T R A C T
Type B Coxsackieviruses (CVBs) are a common cause of acute and chronic myocarditis, dilated cardiomyopathy
and aseptic meningitis. However, no CVB-vaccines are available for human use. We have previously produced
virus-like particles (VLPs) for CVB3 with a baculovirus-insect cell production system. Here we have explored the
potential of a VLP-based vaccine targeting CVB1 and describe the production of CVB1-VLPs with a scalable VLP
puriﬁcation method. The developed puriﬁcation method consisting of tangential ﬂow ﬁltration and ion exchange
chromatography is compatible with industrial scale production. CVB1-VLP vaccine was treated with UV-C or
formalin to study whether stability and immunogenicity was aﬀected. Untreated, UV treated and formalin
treated VLPs remained morphologically intact for 12 months at 4 °C. Formalin treatment increased, whereas UV
treatment decreased the thermostability of the VLP-vaccine. High neutralising and total IgG antibody levels, the
latter predominantly of a Th2 type (IgG1) phenotype, were detected in female BALB/c mice immunised with
non-adjuvanted, untreated CVB1-VLP vaccine. The immunogenicity of the diﬀerently treated CVB1-VLPs (non-
adjuvanted) were compared in C57BL/6 J mice and animals vaccinated with formalin treated CVB1-VLPs
mounted the strongest neutralising and, CVB1-speciﬁc IgG and IgG1 antibody responses. This study demon-
strates that formalin treatment increases the stability and immunogenicity of CVB1-VLP vaccine and may oﬀer a
universal tool for the stabilisation of VLPs in the production of more eﬃcient vaccines.
1. Introduction
The six Coxsackievirus B serotypes (CVB1-6) are common human
pathogens belonging to the family of Enteroviruses (EVs). While the
majority of CVB infections cause mild symptoms, the major importance
of CVBs in public health is associated with their potential for inducing
myocarditis and subsequent cardiomyopathy (Yajima, 2011), aseptic
meningitis (Wong et al., 2011) and pancreatitis (Huber and Ramsingh,
2004). CVB1 became the predominant enterovirus in the United States
in 2007 among neonates (Centers for Disease Control and Prevention
(CDC), 2008) and since then CVB1 epidemics causing life-threatening
infections have occurred in neonates (Verma et al., 2009; Wikswo et al.,
2009; Centers for Disease Control and Prevention (CDC), 2008; Chu
et al., 2015). Moreover, associations between CVB infections (in par-
ticular CVB1) and type 1 diabetes (T1D) have been documented
(Laitinen et al., 2014; Sioofy-Khojine et al., 2018).
All enteroviruses have a similar genetic organization with a 7.5 kb
single-stranded positive-sense RNA genome that is translated into a
single polypeptide containing the P1–P3 regions. The P2 and P3 regions
of the polypeptide contain the non-structural proteins, such as viral
protease 3CD, that cleave the P1 region into the structural proteins VP0,
VP1 and VP3. These structural proteins assemble into the viral capsid,
wherein the viral RNA is encapsidated. VP0 is further processed into
VP2 and VP4 in a viral RNA-driven autocatalysis reaction yielding the
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mature virus (Laitinen et al., 2016). The mature capsid exhibits icosa-
hedral symmetry and consists sixty copies of VP1-4 proteins
(Muckelbauer et al., 1995).
Aside from the polio (Lien and Heymann, 2013) and EV71 (Chang
et al., 2016) vaccines, there are no treatments or vaccines available
against enteroviruses. However, clinical development of a vaccine
against CVBs has recently commenced (Hyoty et al., 2018). EV-vaccines
contain either live-attenuated viruses (oral polio vaccine, OPV) or for-
malin inactivated viruses (inactivated polio vaccine, EV71-vaccine).
However, attenuated and inactivated vaccines face safety issues, such as
reversion to the virulent form. OPV has been shown to regain virulence
through reversion or recombination, resulting in cases of vaccine-as-
sociated paralytic polio (VAPP) and subsequent polio outbreaks
(Lukashev, 2010).
Virus-like particles (VLPs) are empty particles assembled from re-
combinantly expressed viral structural proteins, that lack the viral
genome and are thus non-infectious (Mohsen et al., 2017). As such,
VLP-based vaccines are not associated with safety concerns related to
whole virus vaccines. Various studies have shown that VLPs are pro-
mising vaccine candidates against EVs as demonstrated by monovalent
VLP-vaccines against CVB3 (Zhang et al., 2012; Koho et al., 2014),
EV71 (Salmons et al., 2018), CAV6 (Shen et al., 2016), CAV16 (Liu
et al., 2012) and EV-D68 (Dai et al., 2018) or polyvalent VLP-vaccines
against EV71, CAV6, CAV10 and CAV16 (Zhang et al., 2018a) studied
in preclinical models.
We have previously developed a CVB3-VLP vaccine, which induced
a robust neutralising antibody response in mice (Koho et al., 2014). In
the present study we produced CVB1-VLPs using a new construct design
with the goal to enhance the VLP yield. We also optimised the pur-
iﬁcation process of the VLPs to obtain a production process that would
be applicable for industrial scale production. We analysed the stability
of the CVB1-VLP vaccines, as previous studies have shown that poor
thermal stability of polio-VLPs has restricted their applicability as
vaccines (Adeyemi et al., 2017; Fox et al., 2017). Therefore, we studied
if UV or formalin treatments could improve the stability or im-
munogenicity of the CVB1-VLP-vaccines.
According to our knowledge, other EV-VLP immunogenicity studies
published to date, with the exception of one polio-VLP study (Fox et al.,
2017), have been performed in the presence of adjuvants (Koho et al.,
2014; Zhang et al., 2012, Zhang et al., 2018a, Zhang et al., 2018b;
Salmons et al., 2018; Shen et al., 2016; Liu et al., 2012; Dai et al., 2018;
Wang et al., 2017; Ku et al., 2014). Here, the potential of non-ad-
juvanted CVB1-VLPs as vaccines was demonstrated by the immunisa-
tion of mice. The eﬀect of UV or formalin treatment on vaccine im-
munogenicity of CVB1-VLPs was also examined. Our results provide
insights into the feasibility of non-adjuvanted CVB1-VLPs in the de-
velopment of vaccines against Coxsackie B viruses.
2. Materials and methods
2.1. Generation of the VLP-producing baculoviruses
The baculoviral transfer vector pOET5, containing separate cas-
settes for the CVB1 VP1-4 capsid under control of the polyhedrin pro-
moter and the 3CD-protease under CVM promoter control was ordered
from GeneArt (Regensburg, Germany). A CVB1 ﬁeld isolate (Laitinen
et al., 2014) was chosen as template. The recombinant baculovirus was
produced according to the FlashBAC baculovirus expression system
manual utilising the ﬂashBAC ULTRA baculovirus genome.
2.2. Production and puriﬁcation of the VLPs
CVB1-VLPs were produced in High-Five insect cells. After clar-
iﬁcation by centrifugation (9610×g, 4 °C, 30 min) and ﬁltering through
0.45 μm and 0.2 μm ﬁlters, CVB1-VLPs were concentrated from the
culture supernatant by Tangential Flow Filtration (TFF), utilising 750
MWCO hollow ﬁber with an ÄKTA Flux system. The buﬀer was ex-
changed to 40mM Tris pH 7.5, 10mM MgCl2, 40mM NaCl, 0.1%
Tween80 with the same system. Impurities were removed from the
preparation using HiTrap Q and SP columns (GE Healthcare), as well as
CIMmultus QA and SO3 ion exchange chromatography (IEX) columns
(BIASeparations). Finally, CVB1-VLPs were captured to CIMmultus SO3-
column and eluted using NaCl gradient (peak with 200 mM NaCl).
2.3. Characterisation of the VLPs and vaccine formulation
Puriﬁed VLPs were analysed either on Bolt 4–12% Bis-Tris Plus SDS-
PAGE gels (Invitrogen) and stained with the Pierce Silver Stain Kit
(Thermo Scientiﬁc) or on mini-PROTEAN TGX stain-free precast gra-
dient gels (4–20%) (BioRad). The proteins were analysed by Western
blotting using in-house produced rabbit anti-CVB1-6 polyclonal anti-
body and IRDye-labeled secondary antibody. VLP proteins and im-
purities were assessed by densitometry analysis of SDS-PAGE gels using
the ImageJ software (Schindelin et al., 2012). Determination of VLP
total protein concentration, dynamic light scattering (DLS) analysis and
transmission electron microscopy (TEM) imaging were performed as
described (Hankaniemi et al., 2017). The thermal stability of the VLP
particles was characterized by a thermoﬂuorometric dye-binding assay
using the protein-binding dye SYPRO orange (Invitrogen). Reaction
mixtures of 25 μl containing 4.0 μg VLP and 6 x SYPRO orange were
prepared in PBS and heated from 25 to 110 °C, with ﬂuorescence reads
taken at 1 °C intervals every 30 s within the Biorad quantitative PCR
system.
The vaccine was formulated in M199 medium containing 0.1%
Tween80.
2.4. Mouse immunisations
Female BALB/c OlaHsd mice (Envigo, Horst, the Netherlands) were
vaccinated twice using 50 μl volume intramuscularly (i.m.) on days 0
and 21 with 0.3, 1 or 10 μg of CVB1-VLP (n=5) with no adjuvants.
Mice receiving sterile PBS served as negative controls (n= 5). Whole
blood samples from each mouse were collected at the time of eu-
thanization (day 35) and the serum was separated as described
(Tamminen et al., 2012). All experimental procedures with BALB/c
mice were conducted in accordance with the regulations of the Finnish
National Experiment Board (permission number ESAVI/10800/
04.10.07/2016).
C57BL/6 J mice were vaccinated with subcutaneous injections in-
terscapularly (i.s.) on days 0, 21 and 35 with 1 μg of non-adjuvanted
formalin treated, UV treated, untreated CVB1-VLP or vaccine buﬀer
(n= 10). All experiments with C57BL/6 J mice were conducted at
Karolinska Institutet, Stockholm, Sweden in accordance with the NIH
Principles of Laboratory Animal Care and national laws in Sweden and
were approved by the local ethics committee (permission number S
48–14).
2.5. Neutralisation assays and CVB1-VLP speciﬁc ELISA
Mouse sera were tested for CVB1-speciﬁc IgG and IgG subtype an-
tibodies by ELISA as previously described (Heinimaki et al., 2018).
Brieﬂy, 96-well plates (Corning Inc., Corning, NY) were coated with
50 ng of CVB1-VLPs per well, antibodies were detected with horse-
radish peroxidase-conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis,
MO), IgG1 (Invitrogen) or IgG2a (Invitrogen) and SIGMA FAST OPD
substrate (Sigma-Aldrich). CVB1 neutralising antibodies were measured
as previously described (Laitinen et al., 2014). The dotted line in each
graph represents the positive/negative threshold of neutralising capa-
city (dilution 1:16) in the virus neutralisation assay. According to
previous studies, uninfected animals that have not been vaccinated
occasionally show a neutralising antibody titer of 1:4 but not beyond
this titer (Stone et al., 2018).
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2.6. Statistical analyses
Statistical analyses were performed using GraphPad Prism version
5.02. Neutralising antibody and CVB1-speciﬁc IgG, IgG1 and IgG2a ti-
tres were analysed with Mann-Whitney U test.
3. Results
3.1. Optimised production and puriﬁcation of CVB1-VLPs
CVB1-VLPs were produced in High Five insect cells, isolated from
the clariﬁed insect cell culture supernatants by TFF and puriﬁed with a
combination of subsequent anion and cation exchange chromato-
graphic steps. As ﬁnal puriﬁcation step, VLPs were eluted from the SO3
cation exchange chromatography column at a NaCl concentration of
200mM (Fig. 1a). The yield after puriﬁcation was approximately 3mg/
L, which is approximately six times higher than the yield of CVB3-VLP
in our previous study (Koho et al., 2014). SDS-PAGE analysis and
subsequent silver staining (Fig. 1b, left panel) of the puriﬁed proteins
revealed three prominent proteins of approximately 38 kDa, 31 kDa and
26 kDa corresponding to the CVB1 capsid proteins VP0, VP1 and VP3.
The purity conﬁrmed by silver staining was>95% for the VLP as
measured by densitometric analysis of the SDS-PAGE gel. VP1 and VP3
capsid proteins were also detected by Western Blotting using a rabbit
anti-CVB1-6 polyclonal antibody (Fig. 1b, right panel). DLS analysis
showed that 100% of the particles had an average hydrodynamic dia-
meter of 30.5 (± 0.23) nm and the sample was very monodisperse
(polydispersity index, PdI: 0.065 ± 0.005) indicating that no ag-
gregation or disintegration of VLPs occurred during the production and
puriﬁcation. TEM imaging revealed intact particles with the correct
morphology with an average size of 30 nm (Fig. 1d).
3.2. CVB1-VLPs remain stable for 12 months at 4 °C
An optimal vaccine-candidate is immunogenic and stable during
storage. Chemical crosslinking and genetically engineered disulphides
have been used to improve the stability of viruses and VLPs (Frietze
et al., 2016; Rohovie et al., 2017; Adeyemi et al., 2017; Fox et al.,
2017). We treated the puriﬁed VLP with UV and formalin to study their
eﬀects on VLPs stability and immunogenicity. According to TEM,
treatment by UV or formaldehyde did not aﬀect the morphology of the
VLPs (Fig. 2a–c). An important indicator of the vaccine stability is
particle size, as VLPs might dissociate into subunits or aggregate during
storage, causing changes in particle size and polydispersity index (Pdi),
that both can be monitored by DLS. Here, diﬀerently formulated CVB1-
VLP vaccines were stored at 4 °C in M199-Tween80 buﬀer for twelve
months and analysed by DLS on day 0 as well as after six and twelve
months (Fig. 2d–f). After the twelve months storage period, light scat-
tering intensity and Pdi of untreated, formalin or UV treated VLPs were
found to increase slightly, while the mean particle sizes did not change
(Table 1). These ﬁndings indicate that a minor part of the VLP samples
may have been aggregated during the storage, but in general the VLPs
were stable over 12-month storage.
The concentration of the untreated CVB1-VLP vaccine was de-
termined using a BCA assay. Concentrations of the diﬀerently for-
mulated vaccines from day 0 and after six and twelve months storage at
4 °C were analysed by densitometric analysis, according to which the
concentration of the vaccines did not change during the twelve months
storage period (data not shown). Additionally, the three CVB1 capsid
proteins VP0, VP1 and VP3 were detected by total protein staining of
the vaccines in a SDS-PAGE gel (in some of the samples the VP0 protein
band was blurry in appearance) (Fig. 2g, Supplementary Fig. 1).
3.3. Formalin treatment stabilises CVB1-VLP at elevated temperatures
Previous studies have indicated EV-VLPs to have a lower thermal
Fig. 1. Final cation exchange chromatography
concentration step and characterisation of the
puriﬁed CVB1-VLPs with SDS-PAGE, Western
blotting, DLS and TEM. (A) In the ﬁnal pur-
iﬁcation step, a buﬀer containing 20mM Tris (pH
7.5), 5 mM MgCl2, 20mM NaCl and 0.1%
Tween80 was used as the running buﬀer, and the
same buﬀer containing 2M NaCl was used as the
elution buﬀer. After sample loading, unbound
proteins were washed out from the column with
running buﬀer and column-bound VLPs eluted at
approximately 200mM NaCl concentration using
a linear gradient. (B) SDS-PAGE and Western blot
analyses of puriﬁed VLPs. The left panel shows the
silver-stained SDS-PAGE analysis of VLPs, and in
the right panel VP1 and VP3 capsid proteins were
detected by Western blot using an in-house pro-
duced rabbit anti-CVB1-6 pAb. VLP capsid pro-
teins are indicated with arrows. (C) Dynamic light
scattering analysis of the chromatography-pur-
iﬁed CVB1-VLP. (D) Transmission Electron
Microscopy (TEM) images of the chromatography-
puriﬁed VLPs. Scale bar 50 nm, 25 000× magni-
ﬁcation (boxed region on top), scale bar 100 nm,
15 000× magniﬁcation.
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stability compared to native viruses (Koho et al., 2014; Adeyemi et al.,
2017; Fox et al., 2017), which may be due to a lack of capsid-genome
interactions and also due to the absence of VP0 cleavage. Diﬀerential
Scanning Fluorimetry (DSF) was used to analyse the thermal stability of
the diﬀerently formulated CVB1-VLP vaccines. Two SYPRO orange
peaks were detected, with the ﬁrst (Tm1) being assigned to capsid ex-
pansion (Adeyemi et al., 2017) and exposure of hydrophobic residues,
whereas the second (Tm2) was assigned to denaturation of the VLPs
(Adeyemi et al., 2017) (Fig. 2h). UV treatment lowered the ﬁnal de-
naturation temperature by three centigrade, while formalin treatment
Fig. 2. The stability proﬁles of untreated, UV and formalin treated CVB1-VLP vaccines. Transmission Electron Micrographs of chromatography puriﬁed (A)
untreated, (B) UV treated and (C) formalin treated CVB1-VLP vaccines. Scale bars 100 nm. 25 000× magniﬁcation. VLPs formulated in the vaccine buﬀer
(M199–0.1% Tween80) stored at 4 °C for zero, six and twelve months were analysed by dynamic light scattering (DLS) for their size and volume distributions: (D)
untreated CVB1-VLP, (E) UV treated CVB1-VLP and (F) formalin treated CVB1-VLP. (G) SDS-PAGE analysis of the CVB1-VLP vaccines from day zero and after storing
at 4 °C for six and twelve months. 2 μgs of each vaccine were loaded per well. (H) Thermal stability proﬁle of UV treated, untreated and formalin treated CVB1-VLP
with Diﬀerential Scanning Fluorometry. SYPRO Orange, a ﬂuorescence dye binding to hydrophobic amino acid residues was used to analyse the unfolding or
denaturation of the capsid proteins and, thus the conformational stability of the VLPs. Fluorescence intensity of the dye in the presence of VLPs was plotted as a
function of the temperature, and melting temperatures (Tm) of the VLPs were derived from the inﬂection points of the transition curve using the Boltzmann equation
(Niesen et al., 2007). (I) Tm values of diﬀerent VLP preparations determined from ﬂuorogram. The data is shown as an average of three independent measure-
ments ± Standard Deviation.
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did not aﬀect the ﬁnal denaturation temperature (Fig. 2i). These results
demonstrate, that formalin treatment stabilises the VLP, whereas UV
treatment destabilises it.
3.4. Non-adjuvanted CVB1-VLP vaccines induce robust neutralising
antibody responses in BALB/c and C57BL/6 J mice
To study the immunogenicity of the CVB1-VLPs as vaccines, we ﬁrst
performed a dose response study with the untreated CVB1-VLP in
BALB/c mice. Animals were immunised twice with 0.3 μg, 1 μg or 10 μg
non-adjuvanted CVB1-VLP i.m. (day 0 prime immunisation and day 21
boost immunisation) (Fig. 3a). Sera taken 35 days after the prime im-
munisation were evaluated for their CVB1 neutralising ability in vitro.
All immunised mice generated neutralising antibodies by day 35
(Fig. 3b). There were no statistically signiﬁcant diﬀerences in the re-
sponses between the diﬀerent doses, although the variation within each
group decreased with the increasing dose (Fig. 3b). Geometric mean
titres (GMTs) of the neutralising antibodies were 256, 1351 and 446 for
mice injected with 0.3, 1 and 10 μg CVB1-VLP, respectively.
The immunogenicity of the diﬀerently formulated CVB1-VLP vac-
cines were tested in C57BL/6 J mice by injecting three 1 μg doses of
non-adjuvanted vaccines i.s. to groups of ten mice (Fig. 3c). After the
prime (day 21), boost (day 35) and second boost (day 42) immunisa-
tions, neutralising antibody GMTs were 2, 11 and 97 for the mice im-
munised with untreated CVB1-VLP, 2, 11 and 84 for the mice im-
munised with UV treated CVB1-VLP and 18, 256 and 1351 for the mice
immunised with formalin treated CVB1-VLP. On day 49, the neu-
tralising antibody response had waned for all the CVB1-VLP groups,
being 42 (untreated), 21 (UV treated) and 588 (formalin treated). At all
time points, the group vaccinated with formalin treated CVB1-VLP
mounted signiﬁcantly stronger neutralising antibody responses than the
groups vaccinated with untreated CVB1-VLP or UV treated CVB1-VLP
(Fig. 3d).
3.5. CVB1-VLP vaccine-induced serum IgG antibodies and the proﬁle of
IgG1 and IgG2a antibody responses
In the ﬁrst vaccination experiment, a dose-dependent CVB1-speciﬁc
IgG antibody response was observed in BALB/c mice immunised twice
with 0.3, 1 or 10 μg of untreated CVB1-VLP and the IgG-levels were
signiﬁcantly higher in the group immunised with 1 μg and 10 μg CVB1-
VLP compared to the groups immunised with 0.3 μg (Fig. 4a). On day
35 the GMTs were 16890, 135118 and 178289 for the mice immunised
with 0.3, 1 or 10 μg of untreated CVB1-VLP, respectively.
The dichotomy of IgG1 and IgG2a immunoglobulin subtypes as
markers for Th2 and Th1 type responses was investigated. A strong
dose-dependent Th2 type (IgG1) response was detected for the CVB1-
VLP immunised mice (Fig. 4b), GMTs being 2786, 135118 and 310419
for IgG1 in the groups immunised with 0.3, 1 or 10 μg of untreated
CVB1-VLP. Further, a much weaker CVB1-speciﬁc dose-dependent Th1-
type (IgG2a) response was detected, the GMTs being 800, 2111 and
29407 in the groups immunised with 0.3, 1 or 10 μg CVB1-VLP. How-
ever, the IgG2a-response was signiﬁcantly higher in the group im-
munised with 10 μg compared to 0.3 μg CVB1-VLP (Fig. 4b). Therefore,
the results show an induction of both Th1 and Th2 type responses in
BALB/c mice, with IgG1 antibodies being predominant.
In the second vaccination experiment C57BL/6 J mice immunised
with untreated, UV or formalin treated CVB1-VLP were positive for
CVB1-speciﬁc IgG on day 49 after the prime immunisation, GMTs being
2111, 1600 and 22286, respectively. The strongest IgG response was
detected in mice immunised with formalin treated CVB1-VLP, and the
response was signiﬁcantly higher compared to the group immunised
with untreated CVB1-VLP or UV treated CVB1-VLP (Fig. 4c). Untreated,
UV and formalin treated CVB1-VLP all induced CVB1-speciﬁc Th2 type
(IgG1) responses in C57BL/6 J mice, with the response being sig-
niﬁcantly higher in the formalin treated CVB1-VLP group than in the
UV treated CVB1-VLP group (Fig. 4d). The IgG1 GMTs were 1838, 1213
and 29407 for the mice immunised with untreated, UV or formalin
treated CVB1-VLP. The Th1 type (IgG2a) response was negative for all
groups (Fig. 4d). No CVB1-VLP speciﬁc IgG, IgG1 or IgG2a antibodies
were detected in the sera of BALB/c or C57BL/6 J control mice.
4. Discussion
CVB1-6 are known as the most common viral cause of human heart
infections (Gaaloul et al., 2014). CVBs share many characteristics with
other EVs such as polioviruses, and their manifestations vary from mild
or subclinical to severe and even fatal outcomes (Verma et al., 2009;
Wikswo et al., 2009; Centers for Disease Control and Prevention (CDC),
2008; Chu et al., 2015). The clinical course of CVB1-caused diseases can
vary from cardiac and pancreatic acinar damage to heart failure and
pancreatic deﬁciency (Benjamin et al., 2018). Currently there are no
treatments or vaccines available against CVBs. In the present study, our
objective was to develop an eﬃcient production and puriﬁcation
method for CVB1-VLP and to study its stability and immunogenicity in
two mouse strains.
Commercially available VLP-vaccines, such as HPV vaccine
Cervarix® are based on highly puriﬁed VLPs produced in a baculovirus-
insect cell production system (Artemchuk et al., 2019). Previously, we
have produced a CVB3-VLP vaccine in insect cells and puriﬁed it with
ion exchange chromatography (Koho et al., 2014). In the present study
we aimed to enhance the VLP yield by utilising a similar expression
construct design as for the previously produced EV71-VLP (Lin et al.,
2015) and a baculoviral (ﬂashBAC) genome containing deletions in the
non-essential protease genes (Hitchman et al., 2010). These changes
reduce the toxic eﬀects of enteroviral (Laitinen et al., 2016) and ba-
culoviral proteases (Hitchman et al., 2010) on the production cell line.
The 3CD protease was produced in low levels by utilising CMV
Table 1
DLS analysis of CVB1-VLPs stored at 4 °C.
Day 0 Month 6
d (nm) Vol (%) Pdi SI d (nm) Vol (%) Pdi SI
CVB1-VLP 27.3 ( ± 0.53) 100 ( ± 0.0) 0.13 ( ± 0.04) 7962 ( ± 90) 25.4 ( ± 1.17) 98.8 ( ± 0.47) 0.75 ( ± 0.01) 18603 ( ± 1303)
UV CVB1-VLP 26.7 ( ± 0.44) 99.9 ( ± 0.12) 0.15 ( ± 0.02) 7549 ( ± 70) 25.0 ( ± 0.98) 98.43 ( ± 1.33) 0.86 ( ± 0.09) 19829 ( ± 1566)
Formalin CVB1-VLP 26.1 ( ± 1.0) 100 ( ± 0.0) 0.13 ( ± 0.01) 7078 ( ± 97) 26.6 ( ± 0.64) 96.5 ( ± 1.5) 0.82 ( ± 0.11) 23757 ( ± 1912)
Month 12
d (nm) Vol (%) Pdi SI
CVB1-VLP 25.4 ( ± 0.53) 98.4 ( ± 0.40) 0.85 ( ± 0.13) 16343 ( ± 1870)
UV CVB1-VLP 25.7 ( ± 0.81) 97.3 ( ± 1.0) 1.00 ( ± 0.01) 19438 ( ± 588)
Formalin CVB1-VLP 24.8 ( ± 0.20) 97.8 ( ± 0.58) 0.81 ( ± 0.02) 20524 ( ± 1466)
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promoter, that drives weak expression in insect cells (Lin et al., 2015).
In the CVB1-VLP concentration step we replaced the initial PEG pre-
cipitation step causing a loss of viral particles (Hankaniemi et al., 2017)
with TFF, and further puriﬁcation was performed with ion exchange
chromatography. Both methods are suitable for an industrial scale
production, which is a prerequisite required for the translation of ex-
perimental vaccines to clinical trials.
The stability of vaccines has a major impact on the success of an
immunisation program, and to assure vaccine quality their stability
needs to be evaluated. Immunogenic, but unstable poliovirus-like par-
ticles have been produced previously (Urakawa et al., 1989; Rombaut
and Jore, 1997). To combat the instability and to improve the im-
munogenicity of these VLPs, chemical crosslinking and genetically en-
gineered disulphides have been utilised and these particles have been
shown to be extremely stable, generating high levels of neutralising
antibodies in animal models (Frietze et al., 2016; Rohovie et al., 2017;
Adeyemi et al., 2017; Fox et al., 2017). UV irradiation and formalin
treatments have also been used in the inactivation of poliovirus for
vaccine development (Tano et al., 2007; Furuya et al., 2010). The eﬀect
of formalin treatment on each poliovirus epitope varied, and loss of
viral antigenicity was observed in UV inactivated poliovirus that
showed antigenic and morphological changes (Tano et al., 2007). Si-
milarly, a UV inactivated EV71 vaccine induced a weaker immune re-
sponse than a formalin inactivated EV71 vaccine (Chang et al., 2012)
and similar eﬀects were observed in the case of CVB1 vaccine
(Hankaniemi et al., 2019). Formalin cross-links the functional groups of
amino acids, forming non-reversible methylene bridges (Ramos-Vara,
2005), whereas UV causes the formation of thymine dimers (Battigelli
et al., 1993). In a previous study we observed 12-day formalin treat-
ment to cause CVB1 virus capsid disintegration (Hankaniemi et al.,
2017) and this was also observed with intense UV-C irradiation (un-
published results). In the current study, we studied the eﬀects of UV and
formalin on the stability and immunogenicity of CVB1-VLPs and found
formalin treatment to improve the thermal stability of the capsid and to
enhance the immunogenicity in C57BL/6 J mice, whereas UV treatment
decreased the thermal stability. Therefore, formalin treatment of other
Fig. 3. CVB1-VLP vaccines induce neutralising antibody responses in BALB/c and C57BL/6J mice. (A) Schematic showing the experimental timeline of the
CVB1-VLP vaccinations in BALB/c mice. The immunogenicity of the CVB1-VLP vaccine was tested by twice injecting 0.3, 1 or 10 μg non-adjuvanted vaccine i.m. to
ﬁve mice. (B) CVB1 neutralising titre in the sera of BALB/c mice (n=5) immunised with CVB1-VLP vaccine in samples taken 35 days after the prime vaccination. (C)
Schematic showing the experimental timeline of the vaccinations in C57BL/6 J mice. The immunogenicity of the diﬀerently formulated CVB1-VLP vaccines was
tested in C57BL/6 J mice by a three injections of 1 μg non-adjuvanted vaccines i.s. (D) CVB1 neutralising antibody titres induced by diﬀerently formulated vaccines at
the indicated time points (n=10). Mean neutralising antibody titres are indicated by the line± SEM. Probability values of the diﬀerences between the diﬀerently
formulated vaccines for each time point were determined by Mann-Whitney U test. The dotted line represents the positive/negative threshold of neutralising capacity
(dilution 1:16) in the virus neutralisation assay.
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VLPs might provide a simple method to produce more stable and im-
munogenic entero- and other viral VLP vaccines. We hypothesise that
the virus epitopes inducing the neutralising antibodies and resulting in
protective immunity against CVB1 might be better preserved when the
VLP is treated with formalin. Alternatively, it is possible that the capsid
proteins chemically modiﬁed by formalin act like adjuvants, triggering
a stronger immune response.
The eﬃcacy of most licenced VLP-vaccines has been optimised by
including adjuvants in the vaccine formulas (Cimica and Galarza,
2017). To the best of our knowledge, all immunogenicity studies with
EV-VLPs have also included adjuvants (Zhang et al., 2012, Zhang et al.,
2018a, Zhang et al., 2018b; Dai et al., 2018; Salmons et al., 2018; Shen
et al., 2016; Liu et al., 2012; Koho et al., 2014; Wang et al., 2017; Ku
et al., 2014). Adjuvants are immunomodulatory substances that im-
prove the quality, magnitude and duration of the immune response.
Generally, it is thought that vaccines composed of VLPs may not suf-
ﬁciently trigger the innate immunity response to the level required for
optimal stimulation of the adaptive immune system (Cimica and
Galarza, 2017). However, VLP structures present a repetitive arrange-
ment of antigens that promote B cell activation and can activate a
strong humoral immune response, as well as enhanced T-cell stimula-
tion and cellular immunity (Braun et al., 2012). Therefore, we explored
the immunogenicity potential of CVB1-VLP vaccines without adjuvant
in mice.
CVB infections induce rapid and strong neutralising antibody re-
sponses in humans (Torfason et al., 1987) and mice (Stone et al., 2018;
Svedin et al., 2017) and the protective eﬃcacy of vaccines correlates
well with the magnitude of the antibody response (Stone et al., 2018;
Koho et al., 2014; Hankaniemi et al., 2017; Hankaniemi et al., 2019).
Here, high neutralising and total IgG antibody levels were detected in
female BALB/c mice in a dose-response study using untreated CVB1-
VLP vaccines, and the IgG-response was signiﬁcantly higher with in-
creased vaccine dose. The magnitude of the IgG antibody response and
the preferential patterns of antibody class switching are inﬂuenzed by
the number of immunisations and through the route by which the
vaccine is administered (Vidarsson et al., 2014). Previously it has been
shown that the immune responses of BALB/c and C57BL/6 J mice to
CVB3 infection diﬀer (Leipner et al., 2004). C57BL/6 J mice demon-
strated a stronger IgG response than BALB/c mice, and virus elimina-
tion from the myocardium of C57BL/6 J mice was also more eﬃcient,
with the virus-speciﬁc IgG contributing signiﬁcantly to the rate of CVB3
clearance (Leipner et al., 2004). Most currently licensed vaccines, in-
cluding the inactivated poliovirus vaccine in the market are adminis-
tered either by intramuscular or subcutaneous needle injections (Zhang
et al., 2015). In the current study we wanted to test whether both routes
of administration provide immunity in two mouse strains diﬀering ra-
dically in their Th1/Th2 responses. Therefore, BALB/c mice were im-
munised twice i.m., whereas C57BL/6 J mice were immunised three
times i.s. and both immunisation routes were found to be eﬀective in
mice. However, it is diﬃcult to compare the antibody responses be-
tween the mouse strains because of the diﬀerences in the experimental
set-up. BALB/c mice did produce CVB1-speciﬁc dose-dependent IgG1
antibodies rather than IgG2a antibodies, demonstrating a skew towards
a Th2-type immune response. Also, gender-speciﬁc diﬀerences have
been previously observed in the CVB3-speciﬁc antibody response in
BALB/c mice (Huber and Pfaeﬄe, 1994). CVB3-infected female BALB/c
mice generate more IgG1 isotype than IgG2a, whereas in male mice
IgG2a is more prevalent (Huber and Pfaeﬄe, 1994). Consistent with
these ﬁndings, also we detected a predominantly Th2 type (IgG1)
phenotypic response in the CVB1-VLP vaccinated female BALB/c mice.
Fig. 4. CVB1-VLP speciﬁc serum IgG, IgG1 and IgG2a antibody ELISA responses in BALB/c and C57BL/6J mice. (A and B) Level of anti-CVB1 (A) IgG, (B) IgG1
and IgG2a in the sera of female BALB/c mice vaccinated with diﬀerent CVB1-VLP doses from day 35. (C and D) Level of anti-CVB1 (C) IgG, (D) IgG1 and IgG2a
antibodies in the sera of C57BL/6 J mice vaccinated with untreated, UV treated or formalin treated CVB1-VLPs from day 49. The box plots show the antibody titres,
expressed as the highest sample dilution giving a positive reading (n= 5). The box is deﬁned by the interquartile range (the 25th and 75th percentiles of the
distribution), the horizontal line within the box represents the median (50th percentile) and vertical lines extend to the most extreme observation. The positivity cut-
oﬀ OD value was calculated as follows: control mice mean OD + 3 x SD. An arbitrary titre of 100 (a half of the serum titre 200) was assigned as the positive/negative
threshold (indicated by horizontal line).
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In humans it has been shown that the EV71-neutralising activity is
mainly mediated by the IgG1 isotype and only to a lesser extent by the
IgG2 isotype (Cao et al., 2013). Fittingly, an EV71-VLP vaccine has been
shown to induce high levels of IgG1 (Cao et al., 2015).
When the immunogenicity of diﬀerently treated CVB1-VLPs were
compared in C57BL/6 J mice, we found that formalin treated CVB1-VLP
induced the strongest neutralising antibody and CVB1-speciﬁc IgG re-
sponse. Similarly, formalin treated CVB1-VLP induced signiﬁcantly
higher Th2 type responses in C57BL/6 J mice than untreated and UV
treated CVB1-VLPs, whereas Th1 type (IgG2a) responses were negative
for all CVB1-VLP immunised C57BL/6 J mice.
5. Conclusion
We have developed improved protocols for the production and
puriﬁcation of CVB VLP-vaccines. Immunisations with non-adjuvanted
CVB1-VLPs resulted in high titres of neutralising antibodies and total
IgG antibodies, and a stronger Th2 type (IgG1) rather than Th1 type
(IgG2a) response in mice. Non-adjuvanted CVB1-VLP vaccines are
highly immunogenic and formalin treatment improves their stability
and immunogenicity. Future studies examining the cross-reactivity and
longevity of CVB-VLP elicited immunity should be conducted.
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